PTX3 and cancer: Furthermore, PTX3 has been described to bind apoptotic and cancer cells and modulate complement activation on these cells through engagement of soluble complement inhibitors (Deban et al., 2008; Braunschweig and Jozsi, 2011; Bonavita et al., 2015).